Aptamer‐Incorporated Nanoparticle Systems for Drug Delivery

Charbgoo, Fahimeh; Taghdisi, Seyed Mohammad; Yazdian‐Robati, Rezvan; Abnous, Khalil; Ramezani, Mohammad; Alibolandi, Mona

doi:10.1002/9781119671732.ch5

Cited by 3 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in nucleolin-negative CHO cells, the targeted NPs (Apt-Pepto@DiI) were internalized identically to nontargeted NPs (Pepto@DiI). Previously, it was reported that receptor-mediated endocytosis significantly increased the cellular internalization of the targeted platforms using various ligands comprising peptide, aptamers, and small molecules. ,− …”

Section: Resultsmentioning

confidence: 99%

Synthesis of a Therapeutic Amphiphilic Copolymer of SN38 via RAFT Polymerization and Its Self-Assembly to Peptomicelles for Fighting against Colon Adenocarcinoma

Ram

Babaei

Zolfaghari

et al. 2021

ACS Appl. Polym. Mater.

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the fourth most frequent type and third most lethal malignancy in the world. To increase the efficacy of chemotherapy while reducing its side effects, the self-assembly of polymer−drug conjugates can minimize systemic toxicity while enhancing therapeutic efficiency. In the present study, polyglutamic acid (PGA) was used to prepare the conjugate of a hydrophobic anticancer agent, SN38, by forming an ester bond between phenolic hydroxyl groups of SN38 and the activated carboxylic acid of PGA. Then, a polyhydroxypropyl methacrylamide (PHPMA) block was synthesized starting from the end of the PGA chain via the "grafting from" approach, implementing reversible addition−fragmentation chain transfer (RAFT) polymerization. The amphiphilicity of the synthesized block copolymer will induce self-assembly into peptomicelle (polypeptide-based micellar structure) structures. Then, the prepared SN38-conjugated PGA-PHPMA peptomicelles were tagged with an AS1411 aptamer to provide guided drug delivery to colon adenocarcinoma. The synthesis of the therapeutic diblock copolymer was confirmed by 1 H-NMR. The DLS analysis showed the sizes of 61.44 and 59.10 nm with dispersity (Đ) values of 0.44 and 0.32 for targeted and nontargeted peptomicelles, respectively. In vitro drug release experiments of the prepared system showed a controlled release profile, which was significantly accelerated in citrate buffer (pH 5.4) in comparison with that of phosphate-buffered saline (PBS, 1×, pH 7.4). An in vitro cytotoxicity experiment (MTT) illustrated a higher cytotoxicity for aptamer-targeted peptomicelles in comparison with that of nontargeted ones against H29 and C26 as nucleolin-positive cell lines, which was statistically significant, while no difference was identified between the toxicity of aforementioned formulation against CHO as a nucleolin-negative cell line (p > 0.05). In vivo study on mice bearing C26 colon carcinoma confirmed the superior therapeutic index of the aptamer-targeted peptomicelles in comparison with nontargeted peptomicelles in terms of tumor growth suppression and survival rate. Polypeptide-based self-assembled therapeutic structures as an innovative platform represent a capable chemotherapy approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Synthesis of a Therapeutic Amphiphilic Copolymer of SN38 via RAFT Polymerization and Its Self-Assembly to Peptomicelles for Fighting against Colon Adenocarcinoma

Ram

Babaei

Zolfaghari

et al. 2021

ACS Appl. Polym. Mater.

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, aptamer-drug complex systems face major limitations of insufficient drug release and aptamer binding to the target site. Hence, to overcome these limitations aptamer-modified nanoparticles have been proposed in cancer therapeutics. , Among them, liposomal nanoparticles have been recognized as versatile systems in targeted cancer therapeutics . Aptamer attached liposomes exhibit better targeting and therapeutic response to cancer cells as compared to nontargeting liposomes.…”

Section: Liposomes In Solid Tumor Theranosticsmentioning

confidence: 99%

Engineered Liposomes in Interventional Theranostics of Solid Tumors

Kommineni

Chaudhari

Conde

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Engineered liposomal nanoparticles have unique characteristics as cargo carriers in cancer care and therapeutics. Liposomal theranostics have shown significant progress in preclinical and clinical cancer models in the past few years. Liposomal hybrid systems have not only been approved by the FDA but have also reached the market level. Nanosized liposomes are clinically proven systems for delivering multiple therapeutic as well as imaging agents to the target sites in (i) cancer theranostics of solid tumors, (ii) image-guided therapeutics, and (iii) combination therapeutic applications. The choice of diagnostics and therapeutics can intervene in the theranostics property of the engineered system. However, integrating imaging and therapeutics probes within lipid self-assembly “liposome” may compromise their overall theranostics performance. On the other hand, liposomal systems suffer from their fragile nature, site-selective tumor targeting, specific biodistribution and premature leakage of loaded cargo molecules before reaching the target site. Various engineering approaches, viz., grafting, conjugation, encapsulations, etc., have been investigated to overcome the aforementioned issues. It has been studied that surface-engineered liposomes demonstrate better tumor selectivity and improved therapeutic activity and retention in cells/or solid tumors. It should be noted that several other parameters like reproducibility, stability, smooth circulation, toxicity of vital organs, patient compliance, etc. must be addressed before using liposomal theranostics agents in solid tumors or clinical models. Herein, we have reviewed the importance and challenges of liposomal medicines in targeted cancer theranostics with their preclinical and clinical progress and a translational overview.

show abstract